https://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-manyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-manyhttps://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-many#u53064Mon, 31 Aug 2026 11:22:18 +0000The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval coincides with a broader shift toward personalized cancer treatment, highlighted by a breakthrough from Moderna and Merck. Their personalized mRNA cancer vaccine successfully prevented melanoma recurrence in late-stage trials. Experts describe these developments as the start of an era where vaccines and targeted inhibitors train the immune system to fight a specific patient's cancer, offering new options for diseases traditionally considered dea https://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-manyhttps://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-many#u51835Sat, 29 Aug 2026 13:57:41 +0000The US FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. This approval marks a new approach to treating the disease, which is notoriously deadly. Some patients, including former University of Florida President Sasse, have already received the medication, crediting it with extending their life.Why it mattersPancreatic cancer has limited treatment options and poor survival rates. The approval of daraxonrasib offers hope for improved treatment outcomes. This development is part of a larger effort to develop effective tr https://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-manyhttps://www.live-feeds.com/feed/new-drug-approved-by-f-d-a-for-pancreatic-cancer-could-be-first-of-many#u50617Fri, 28 Aug 2026 07:50:29 +0000The Food and Drug Administration approved a first-of-a-kind pill from Revolution Medicines on Wednesday to treat pancreatic cancer. The drug is designed to improve survival rates for a disease noted for being notoriously deadly. Some patients at Dartmouth are among the first to receive the medication. Former University of Florida President Sasse credited the drug with extending his life. This approval marks a new approach to treating the disease and has sparked a race to develop similar medicines.Why it mattersPancreatic cancer is traditionally difficult to treat with high mortality rates. Thi